Cargando…

The A–Z of Zika drug discovery

Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A–Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mottin, Melina, Borba, Joyce V.V.B., Braga, Rodolpho C., Torres, Pedro H.M., Martini, Matheus C., Proenca-Modena, Jose Luiz, Judice, Carla C., Costa, Fabio T.M., Ekins, Sean, Perryman, Alexander L., Horta Andrade, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108251/
https://www.ncbi.nlm.nih.gov/pubmed/29935345
http://dx.doi.org/10.1016/j.drudis.2018.06.014
Descripción
Sumario:Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A–Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computationally guided compounds, including discovered viral and host cell inhibitors. Promising ZIKV molecular targets are also described and discussed, as well as targets belonging to the host cell, as new opportunities for ZIKV drug discovery. All this knowledge is not only crucial to advancing the fight against the Zika virus and other flaviviruses but also helps us prepare for the next emerging virus outbreak to which we will have to respond.